Eye disease in sickling disorders.

Hematol Oncol Clin North Am

Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Published: December 1996

When treating patients with sickling disorders, hematologists and oncologists should know those eye lesions that require referral to an ophthalmologist, those that should lead to referral, and those that rarely are associated with decreased vision. Hyphema in any patient whose red cells contain hemoglobin S falls into the first category. Retinal neovascularization (proliferative retinopathy) and its consequence vitreous hemorrhage fall into the second. The comma sign, angioid streaks, and abnormal color vision fall into the third category. The roles of preoperative transfusion and experimental antisickling therapy in treatment and prevention of eye lesions are incompletely defined at present.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0889-8588(05)70406-8DOI Listing

Publication Analysis

Top Keywords

sickling disorders
8
eye lesions
8
eye disease
4
disease sickling
4
disorders treating
4
treating patients
4
patients sickling
4
disorders hematologists
4
hematologists oncologists
4
oncologists eye
4

Similar Publications

Sickle Cell Anemia and Inflammation: A Review of Stones and Landmarks Paving the Road in the Last 25 Years.

Hematol Rep

January 2025

Laboratory of Immunobiology and Immunogenetics, Post Graduation Program in Genetics and Molecular Biology (PPGBM), Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre 91501-970, Brazil.

A quarter of a century ago, sickle cell disease (SCD) was mainly viewed as a typical genetic disease inherited as a classical Mendelian trait. Therefore, the main focus concerning SCD was on diagnosis, meaning, genotyping, and identification of homozygous and heterozygous individuals carrying the relevant HbS mutant allele. Nowadays, it is well established that sickle cell disease is indeed the result of homozygosis for the HbS variant, although this single feature is not capable of explaining the highly diverse clinical presentation of SCD.

View Article and Find Full Text PDF

Background: Red blood cell (RBC) utilization in patients with sickle cell disease (SCD) in Canada is poorly defined. This study describes RBC utilization in an SCD cohort at a single Canadian center.

Study Design And Methods: All adults with SCD who received care at the Ottawa Hospital between January 2006 and May 2019 were included, and followed until December 2021.

View Article and Find Full Text PDF

Sickle cell disease (SCD) is the most common genetic disease in the world and a societal challenge. SCD is characterized by multi-organ injury related to intravascular hemolysis. To understand tissue-specific responses to intravascular hemolysis and exposure to heme, we present a transcriptomic atlas in the primary target organs of HbSS vs HbAA transgenic SCD mice.

View Article and Find Full Text PDF

Background And Objective: Sickle cell disease (SCD) is a vascular disease that may affect the retina. This study aimed to evaluate differences in average velocity (AV, mm/s), blood flow (BF, μL/min) and vessel diameter (VD, μm) from the temporal retinal arcades in SCD compared to healthy eyes using Doppler optical coherence tomography (DOCT).

Patients And Methods: A cross-sectional study was conducted between 2021 and 2023.

View Article and Find Full Text PDF

Introduction: Newborn Screening (NBS) is a public health program designed to identify and provide early interventions for infants with genetic disorders such as Sickle Cell Disease (SCD). Lack of awareness and unwillingness to participate in the NBS by caregivers and some healthcare workers are major contributing factors impeding NBS for SCD.

Objective: To evaluate the level of awareness and acceptance of NBS for SCD and the determinant factors influencing caregivers in Gwagwalada Area Council of the Federal Capital Territory, Abuja, Nigeria.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!